ReviewBiomedicines2022

The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.

Andrew PachnerPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.